Commonwealth Equity Services
CLRB icon

Commonwealth Equity Services’s Cellectar Biosciences CLRB Stock Holding History

Commonwealth Equity Services’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-402
Closed -$4K – 4270
2025
Q1 		$4K Hold
402
– – ﹤0.01% 4166
2024
Q4 		$4K Buy
+402
New +$18.6K ﹤0.01% 4084
2022
Q3 		– Sell
-123
Closed -$14K – 3677
2022
Q2 		$14K Hold
123
– – ﹤0.01% 3603
2022
Q1 		$25K Hold
123
– – ﹤0.01% 3639
2021
Q4 		$24K Buy
123
+8
+7% +$1.93K ﹤0.01% 3590
2021
Q3 		$31K Buy
115
+25
+28% +$7.63K ﹤0.01% 3527
2021
Q2 		$32K Buy
90
+14
+18% +$6.07K ﹤0.01% 3483
2021
Q1 		$36K Buy
76
+25
+49% +$14.9K ﹤0.01% 3355
2020
Q4 		$32K Buy
+51
New +$23.4K ﹤0.01% 3158

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Commonwealth Equity Services's CLRB Position: Q2 2025 in Review

Commonwealth Equity Services sold out of Cellectar Biosciences (CLRB) in Q2 2025, closing a stake of 402 shares — an estimated $4K sold.

Commonwealth Equity Services first reported a position in CLRB in Q4 2020 and held it in 9 quarters. The position peaked at $36K in Q1 2021. 19 funds tracked by Wall St. Rank hold CLRB as of Q2 2025.

  • Commonwealth Equity Services reported no remaining Cellectar Biosciences position as of Q2 2025 after selling out during the quarter.
  • Commonwealth Equity Services sold 402 Cellectar Biosciences shares in Q2 2025, an estimated $4K.
  • Commonwealth Equity Services first reported a position in Cellectar Biosciences in Q4 2020 and held it in 9 quarters.
  • Commonwealth Equity Services's Cellectar Biosciences position peaked at $36K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2025.

Based on Commonwealth Equity Services's 13F filing for Q2 2025, filed 6 Aug 2025.